FDA Approves Ozurdex for Treatment of Uveitis Affecting Posterior Segment of Eye

September 28, 2010

In late September, Allergan announced that announced that the FDA had approved OZURDEX(R) (dexamethasone intravitreal implant) 0.7 mg for the treatment of non-infectious ocular inflammation, or uveitis, affecting the posterior segment of the eye. Posterior uveitis is the cause of 10 to 15 percent of cases of blindness in the United States.

OZURDEX(R) is a biodegradable implant that delivers an extended release of the corticosteroid dexamethasone via intravitreal injection with Allergan’s proprietary and innovative NOVADUR(R) solid polymer delivery system.

Read Allergan’s full press release here.




Jump down to form below to submit your own comments

Comments are closed.